You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 18, 2024

OMONTYS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Omontys, and when can generic versions of Omontys launch?

Omontys is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

DrugPatentWatch® Generic Entry Outlook for Omontys

Omontys was eligible for patent challenges on March 27, 2016.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for OMONTYS
International Patents:114
US Patents:6
Applicants:1
NDAs:1
Clinical Trials: 18
Formulation / Manufacturing:see details
DailyMed Link:OMONTYS at DailyMed
Drug patent expirations by year for OMONTYS
Recent Clinical Trials for OMONTYS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AmgenPhase 4
AffymaxPhase 3
TakedaPhase 3

See all OMONTYS clinical trials

US Patents and Regulatory Information for OMONTYS

OMONTYS is protected by six US patents.

Patents protecting OMONTYS

Peptides that bind to the erythropoietin receptor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Peptides that bind to the erythropoietin receptor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Peptides that bind to the erythropoietin receptor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Spacer moiety for poly (ethylene glycol) modified peptide based compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OMONTYS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for OMONTYS

See the table below for patents covering OMONTYS around the world.

Country Patent Number Title Estimated Expiration
Brazil PI0411172 peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica ⤷  Try a Trial
Japan 2007530439 ⤷  Try a Trial
European Patent Office 1629007 NOUVEAUX PEPTIDES SE FIXANT AU RECEPTEUR DE L'ERYTHROPOIETINE (NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR) ⤷  Try a Trial
Denmark 1629007 ⤷  Try a Trial
Singapore 160224 NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR ⤷  Try a Trial
Japan 4949844 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.